3 transcripts
FGEN
Earnings call transcript
NASDAQ
2024 Q2
6 Aug 24
as a Precision Promise adaptive platform trial. This was simply not the result. We would like to thank the patients and clinical trial investigators
FGEN
Earnings call transcript
NASDAQ
2023 Q4
26 Feb 24
at having prophylactic GCSF as part of the Phase II study design. This was incorporated into the investigator-sponsored combination trial
FGEN
Earnings call transcript
NASDAQ
2023 Q2
7 Aug 23
52 compared to baseline. FibroGen would like to thank the patients, caregivers and clinical trial investigators for their dedication to participating
- Prev
- 1
- Next